{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"A prospective, non interventional study of tivozanib monotherapy as first-line therapy for patients with advanced renal cell carcinoma and with favorable or intermediate IMDC risk","eudractNumber":null,"id":11560,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T09:28:53+02:00","shortTitle":"Tivoli","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A Phase 3 Randomized Study Comparing JNJ-79635322 and&#160;</div><div>an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody</div>","eudractNumber":"2025-522007-18","id":11964,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07258511","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T12:17:39+02:00","shortTitle":"Trilogy-4","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Einseitige Implantation des SPIRION Kehlkopfschrittmachers bei Patienten ohne vorherige permanente Glottis-Erweiterung<div><b><br /></b></div><div><b>DRKS00032341</b></div><div><b><br /></b></div><div><p class=\"MsoListParagraph\" style=\"text-indent:-18pt;\">-&#160; &#160; &#160; Studie mit keiner\nVoroperation am Kehlkopf (ULP)</p></div><div><b><br /></b></div>","eudractNumber":null,"id":8774,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06007170 ","phase":null,"recruitmentStart":"2023-08-18T09:11:34+02:00","shortTitle":"ULP_2022CIP001 Studie mit keiner Voroperation am Kehlkopf","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Effekt von hochdosiertem Vitamin D3 auf die 28-Tages-Mortalit&#228;t bei erwachsenen kritisch kranken Patienten mit schwerem Vitamin D Mangel: eine multizentrische, Placebo-kontrollierte, doppelblinde Phase III Studie<div>Eudra-CT:&#160;2016-002460-13</div>","eudractNumber":"2024-514556-32-00","id":8204,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-03-20T13:38:53+01:00","shortTitle":"VITDALIZE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Beobachtungsstudie zum Einsatz von Venetoclax bei Patienten mit chronisch lymphatischer Leuk&#228;mie (LCC) unter realen Versorgungsbedingungen","eudractNumber":null,"id":4866,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"},{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"}],"nctNumber":"NCT03342144","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T08:57:14+01:00","shortTitle":"VeRVe","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Verbesserung der Versorgungsqualit&#228;t durch standardisierte Dokumentation d-uo VERSUS","eudractNumber":null,"id":10722,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-11T10:24:40+01:00","shortTitle":"Versus","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":9618,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-02-23T10:10:34+01:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":7969,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-06-01T13:24:07+02:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wirksamkeit\n/ Effekte einer Yogatherapie bei Patienten mit hirneigenem Tumor WHO&#176; Grad III\nund IV und deren Angeh&#246;rigen<div><br /></div><div><b>DRKS00029554</b><br /></div><div><b><br /></b></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":4430,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2019-02-01T10:00:57+01:00","shortTitle":"YINOTA-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Effekte von Yoga auf Angst, Unruhe, Schlafqualit&#228;t und Fatigue bei Frauen mit der Erstdiagnose Brustkrebs &#8211; eine randomisierte kontrollierte Studie","eudractNumber":null,"id":10894,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-01-01T10:38:07+01:00","shortTitle":"Yoga-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}